DexCom, Inc. - Common Stock (DXCM)

As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.

DexCom Q3 2025 earnings beat estimates, but stock fell due to full-year revenue guidance that missed analyst expectations.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.

The company hasn't had a great year. Is it about to turn things around?

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know.

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023.

Both companies have faced recent challenges, but look likely to overcome them.

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q2 patient monitoring earnings season.

Dexcom offers strong growth in diabetes care with solid profitability and a reasonable valuation, fitting an affordable growth investment strategy.

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.

Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

10 analysts have expressed a variety of opinions on DexCom (NASDAQ: DXCM) over the past quarter, offering a diverse set of opinions from bullish to bearish.